Cytek Biosciences, Inc. (CTKB) Financial Analysis & Valuation | Quarter Chart
Cytek Biosciences, Inc. (CTKB)
CTKBPrice: $4.6
Fair Value: 🔒
🔒score
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing th... more
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facili... more
Description
Shares
| Market Cap | $591.33M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Wenbin Jiang |
| IPO Date | 2021-07-23 | CAGR | 0.23% |
| Employees | 663 | Website | cytekbio.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 7.79% | Total Yield | 7.79% |
CTKB chart loading...
Fundamentals
Technicals
| Enterprise Value | $588.92M | P/E Ratio | -8.85 |
| Forward P/E | 17.66 | PEG Ratio | — |
| P/S Ratio | 1.62 | P/B Ratio | 0.95 |
| P/CF Ratio | -70.63 | P/FCF Ratio | -37.65 |
| EPS | $-0.52 | EPS Growth 1Y | 1004.49% |
| EPS Growth 3Y | -3087.86% | EPS Growth 5Y | -437.4% |
| Revenue Growth 1Y | 0.52% | Gross Margin | 0.52% |
| Operating Margin | -0.2% | Profit Margin | -0.33% |
| ROE | -0.18% | ROA | -1147.22% |
| ROCE | 0.52% | Current Ratio | 5.04 |
| Quick Ratio | 5.04 | Cash Ratio | 1.17 |
| Debt/Equity | 0.04 | Interest Coverage | -20.99 |
| Altman Z Score | 5803.15 | Piotroski Score | 3 |